Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenerimod QTc interval and drug interaction study in healthy volunteers
NCT04255277Phase 1Completed
- Sponsor
- Viatris
- Start
- Jan 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cenerimod (4 arms), sponsored by Viatris. Primary endpoints: Placebo-corrected, change-from-baseline QTcF at 56 days, Maximum plasma concentration of levonorgestrel and 11 more. Started Jan 2020; status: completed.
02
Drugs
cenerimod
Beyond the preview
Go deeper on NCT04255277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04255277.